Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.

ABSTRACT:

Background

PRO 140 (a humanized form of the PA14 antibody, a monoclonal CCR5 antibody) inhibits CCR5-tropic (R5) type 1 human immunodeficiency virus (HIV). This may be an effective new treatment with the potential to address the limitations of currently available therapies for HIV-infected patients.

Objectives

We aimed to assess the efficacy, safety, clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140 for HIV-infected patients in randomized controlled trials (RCTs) and quasi-randomized controlled trials (quasi-RCTs).

Search methods

We searched databases including The Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 4), MEDLINE (PubMed, January 1966 to April 201

SUBMITTER: Li L 

PROVIDER: S-EPMC7173721 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature